capecitabine has been researched along with Cancer of Prostate in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bydder, G; Bydder, M; Carmona, R; Gulaya, S; Mell, LK; Pritz, J; Vaida, F; Welch, CS; Williamson, CW; Zhu, H | 1 |
| Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA | 1 |
| Al Hasan, SA; Cher, ML; Dickow, B; Eliason, J; Heilbrun, LK; Marur, S; Smith, DW; Vaishampayan, UN | 1 |
| Njiaju, UO; Truica, CI | 1 |
| Abadie-Lacourtoisie, S; Brain, E; Esterni, B; Fargeot, P; Geneve, J; Joly, F; Laguerre, B; Luporsi, E; Retornaz, F; Rousseau, F; Servent, V | 1 |
| Andreesen, R; Berand, A; Reichle, A; Rogenhofer, S; Vogelhuber, M; Walter, B; Wieland, WF | 1 |
| Alberola Candel, V; Cerezuela Fuentes, P; Gasent Blesa, JM; Giner Marco, V; Giner-Bosch, V | 1 |
| Fan, WF; Liu, FY; Meng, LJ; Pu, XL; Wang, J; Yang, M | 1 |
| Black, CA; El-Rayes, BF; Ensley, JF | 1 |
| Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M | 1 |
| Bolunwu, N; Chan, S; Kendall, A; Pandha, H; Plunkett, T; Somaiah, N; Spicer, J | 1 |
| Dieringer, P; Jonasch, E; Mathew, P; Pagliaro, LC; Rodney, A; Tannir, N | 1 |
| Cavaglione, G; Chamorey, E; Dides, S; Ferrero, JM; Foa, C; Kaphan, R; Lesbats, G; Nouyrigat, P; Oudard, S | 1 |
| Coras, B; Hafner, C; Landthaler, M; Reichle, A; Vogt, T | 1 |
| Asmar, L; Boehm, KA; Ilegbodu, D; Kolodziej, M; Mull, S; Neubauer, MA; Perrine, G; Pluenneke, RE; Rousey, SR | 1 |
| Hartley, A; Ho, K; Muscroft, T; Sanghera, P | 1 |
| Bradley, D; Dunn, RL; Friedman, J; Hussain, M; Montie, J; Sarkar, FH; Shah, RB; Vaishampayan, U; Wood, D; Wu, A | 1 |
10 trial(s) available for capecitabine and Cancer of Prostate
| Article | Year |
|---|---|
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Etidronic Acid; Fluorouracil; Humans; Male; Middle Aged; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radioisotopes; Radiopharmaceuticals; Rhenium | 2009 |
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Prognosis; Prostatectomy; Prostatic Neoplasms; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2009 |
Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamethasone; Disease Progression; Drug Therapy, Combination; Etoricoxib; Fluorouracil; Humans; Kaplan-Meier Estimate; Lactones; Male; Orchiectomy; Pioglitazone; Prostatic Neoplasms; Pyridines; Sulfones; Thiazolidinediones; Treatment Outcome | 2010 |
Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Prostatic Neoplasms; Survival Analysis | 2011 |
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Hormones; Humans; Male; Middle Aged; Neoplasm Metastasis; Prodrugs; Prostatic Neoplasms; Quality of Life; Survival Analysis | 2004 |
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms | 2005 |
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Probability; Prognosis; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
7 other study(ies) available for capecitabine and Cancer of Prostate
| Article | Year |
|---|---|
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Capecitabine; Cervical Vertebrae; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Endometrial Neoplasms; Female; Fluorouracil; Humans; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Paclitaxel; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Spine; Thoracic Vertebrae; Uterine Cervical Neoplasms | 2014 |
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Capecitabine; Carotid Stenosis; Coronary Artery Disease; Cyclophosphamide; Deoxycytidine; Diabetes Mellitus; Fluorouracil; Humans; Immunohistochemistry; Leuprolide; Male; Nitriles; Osteoarthritis; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Pulmonary Disease, Chronic Obstructive; Tomography, X-Ray Computed; Tosyl Compounds | 2010 |
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fluorouracil; Follow-Up Studies; Humans; Male; Prednisone; Prostatic Neoplasms; Retrospective Studies; Thalidomide | 2012 |
Hormone-refractory prostate cancer responding to capecitabine.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabine; Deoxycytidine; Fluorouracil; Goserelin; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Failure; Treatment Outcome | 2003 |
Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Capecitabine; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Liver Neoplasms; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Paraneoplastic Syndromes; Pioglitazone; Prostatic Neoplasms; Thiazolidinediones | 2006 |
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Transitional Cell; Colonic Pouches; Deoxycytidine; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Rectal Neoplasms; Urinary Bladder Neoplasms | 2007 |
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids | 2008 |